A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus

Br J Dermatol. 2019 May;180(5):964-965. doi: 10.1111/bjd.17344.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Comment

MeSH terms

  • Azetidines*
  • Double-Blind Method
  • Humans
  • Lupus Erythematosus, Cutaneous*
  • Lupus Erythematosus, Systemic*
  • Sulfonamides

Substances

  • Azetidines
  • Sulfonamides
  • baricitinib